As the COVID-19 variant KP.2 spreads rapidly in the U.S., will Novavax's fall vaccine approval ignite another stock surge?

As the KP.2 variant spreads rapidly in the United States, Novavax's JN.1 vaccine demonstrates effective neutralizing responses, proving its capability to adapt to viral evolutions. The vaccine has received WHO endorsement and is scheduled for distribution in the U.S. this fall, pending FDA approval. These developments highlight Novavax's strategic presence in the global vaccine market and its rapid response capabilities, offering new growth and profit opportunities for investors. As the demand for effective vaccines continues globally, Novavax's performance in vaccine development and market response could drive its stock price upward.